AGIOS PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AGIOS PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $30.01M | Feb 14, 2019 |
| FY2018 | Sep 30, 2018 | $15.20M | Feb 14, 2019 |
| FY2018 | Jun 30, 2018 | $40.41M | Feb 14, 2019 |
| FY2018 | Mar 31, 2018 | $8.76M | Feb 14, 2019 |
| FY2018 | Dec 31, 2017 | $9.80M | Feb 14, 2019 |
| FY2018 | Sep 30, 2017 | $11.36M | Feb 14, 2019 |
| FY2018 | Jun 30, 2017 | $11.35M | Feb 14, 2019 |
| FY2018 | Mar 31, 2017 | $10.51M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $22.65M | Feb 14, 2018 |
| FY2017 | Sep 30, 2016 | $8.99M | Feb 14, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.03M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $36.50M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $26.82M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $14.24M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $0 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $44.05M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $34.71M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $37.35M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $87.10M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $35.44M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($412.78M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $673.73M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($352.09M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($231.80M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.60B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($327.37M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($411.47M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($346.03M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($314.67M) | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | ($198.47M) | Feb 14, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($472.13M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($425.74M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($391.49M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($389.05M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | ($378.42M) | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | ($92.43M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($90.33M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($90.20M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($43.19M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($105.93M) | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $339.54M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $301.29M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $295.53M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $279.91M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $256.97M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $220.81M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $214.26M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $341.32M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $292.68M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $220.16M | Feb 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $180.28M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $156.78M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $119.90M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $121.67M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $121.45M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $115.11M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $102.01M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $114.15M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $71.12M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $50.71M | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($372.98M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($389.84M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($296.06M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($309.48M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | ($407.32M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($290.76M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($370.62M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($304.42M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($285.23M) | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $38.56M | Feb 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.32M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.69M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $999.0K | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $4.88M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $5.74M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $14.11M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $12.03M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $6.99M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $4.63M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $9.92M | Feb 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.66B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $937.12M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.24B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.44B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $852.95M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $890.74M | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $858.46M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $614.40M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $619.09M | Feb 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.11M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $122.24M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $126.10M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $137.90M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $145.76M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $453.45M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $250.21M | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $170.92M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $238.89M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $260.50M | Feb 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.19B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.54B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $811.02M | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | $1.10B | Feb 12, 2026 |
| FY2024 | Dec 31, 2021 | $1.29B | Feb 13, 2025 |
| FY2023 | Dec 31, 2020 | $399.50M | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | $640.53M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $687.54M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $375.50M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $358.59M | Feb 19, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($561.71M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($148.92M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($822.65M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($470.56M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($238.76M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($1.84B) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($1.52B) | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | ($1.10B) | Feb 25, 2021 |
| FY2020 | Jan 1, 2018 | ($758.61M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | ($798.06M) | Feb 14, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.13M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $76.25M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $88.21M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $139.26M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $203.13M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $127.44M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $80.93M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $70.50M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $102.72M | Feb 14, 2019 |
| FY2018 | Dec 31, 2016 | $160.75M | Feb 14, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | (6) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 13, 2025 |
| FY2021 | Dec 31, 2021 | (1) | Feb 24, 2022 |
| FY2021 | Sep 30, 2021 | (1) | Feb 24, 2022 |
| FY2021 | Jun 30, 2021 | (1) | Feb 24, 2022 |
| FY2021 | Mar 31, 2021 | 26 | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | (1) | Feb 24, 2022 |
| FY2021 | Sep 30, 2020 | (1) | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | (6) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 13, 2025 |
| FY2021 | Dec 31, 2021 | (1) | Feb 24, 2022 |
| FY2021 | Sep 30, 2021 | (1) | Feb 24, 2022 |
| FY2021 | Jun 30, 2021 | (1) | Feb 24, 2022 |
| FY2021 | Mar 31, 2021 | 26 | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | (1) | Feb 24, 2022 |
| FY2021 | Sep 30, 2020 | (1) | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 58.45M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 57.16M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 55.95M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 55.04M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 54.33M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 69.29M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 68.40M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 58.22M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | 48.83M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | 42.22M | Feb 14, 2018 |